Explore Your Local Site

Looks like you've landed on our   site. Let's take you home:   United Kingdom

Please note that the content and products on the    site might not be available in your region.

 

United Kingdom Homepage
Continue on the current website:  

 

ClariSIGMAM

ClariSIGMAM is a fully automated, zero-click breast density assessment solution.1

Request Quote

ClariSigmam Logo
  • Intracranial Hemorrhage
  • Triage
  • Non-Contrast
  • Head
  • CT

The Challenge With Dense Breasts

Women presenting with dense breasts are at twice the risk of developing breast cancer,2-4 and the excess amount of fibroglandular tissue is a challenge when detecting tumors on a mammogram.5-6

 

 

Automatically Calculate Percent Breast Density in Zero Clicks

ClariSIGMAM is a software application intended for use with compatible full-field digital mammography systems by calculating percent breast density, which is defined as the ratio of fibroglandular tissue to estimated total breast area.

 

ClariSIGMAM uses this numerical value to provide breast density group information (BI-RADSA+Bas fatty and BI-RADSC +Das dense) to aid you in the assessment of breast tissue composition.1

 

Consistency.
Compliance.
Seamless Workflows.

Blue chart

Helps ensure that clinicians make consistent clinical decisions in an objective and convenient way1

Hand Icon

Consistent standardized report format to help comply with breast density notification laws1-8

Seamless

Seamless integration with PACS9

Request a demo

Applications Tailored to You

Discover how our tailored service lines and applications can better suit your needs.

Find Out More

    1. ClariSIGMAM User Manual

    2. Mann RM, Athanasiou A, Baltzer PAT, et al. Breast cancer screening in women with extremely dense breasts recommendations of the European Society of Breast Imaging (EUSOBI). Eur Radiol.2022;32(6):4036-4045.

    3. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1159-1169.

    4. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007;356(3):227-236.

    5. NIH National Cancer Institute. Dense Breasts: Answers to Commonly Asked Questions. Accessed April 18, 2023. https://www.cancer.gov/types/breast/breast-changes/dense-breasts

    6. Centers for Disease Control and Prevention (CDC). What Are the Risk Factors for Breast Cancer? Accessed April 18, 2023. https://www.cdc.gov/cancer/breast/basic_info/risk_factors.htm

    7. VII Performance Data

    8. Densebreast-info. FDA National Reporting Standard. Accessed April 18, 2023. https://densebreast-info.org/legislativeinformation/national-reporting-standard/

    9. Claripi 510K K203785

    1. ClariSIGMAM User Manual

    2. Mann RM, Athanasiou A, Baltzer PAT, et al. Breast cancer screening in women with extremely dense breasts recommendations of the European Society of Breast Imaging (EUSOBI). Eur Radiol.2022;32(6):4036-4045.

    3. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1159-1169.

    4. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007;356(3):227-236.

    5. NIH National Cancer Institute. Dense Breasts: Answers to Commonly Asked Questions. Accessed April 18, 2023. https://www.cancer.gov/types/breast/breast-changes/dense-breasts

    6. Centers for Disease Control and Prevention (CDC). What Are the Risk Factors for Breast Cancer? Accessed April 18, 2023. https://www.cdc.gov/cancer/breast/basic_info/risk_factors.htm

    7. VII Performance Data

    8. Densebreast-info. FDA National Reporting Standard. Accessed April 18, 2023. https://densebreast-info.org/legislativeinformation/national-reporting-standard/

    9. Claripi 510K K203785

    What Customers Are Saying

     

    The application enables identification of small nodules faster and more reliably, particularly for oncological patients.

     

    Terrence Matalon
    MD, Chairman, Diagnostic Radiology at Einstein Medical Center
     

      1. Nam liber tempor cum soluta nobis eleifend option congue nihil imperdiet doming

      2. Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Magna aliquam erat volutpat tempo molestie vesse

      1. Nam liber tempor cum soluta nobis eleifend option congue nihil imperdiet doming

      2. Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Magna aliquam erat volutpat tempo molestie vesse